Preclinical AD Workgroup staging: Pathological correlates and potential challenges

Neurobiology of Aging

Volumn 33, Issue 3, 2012, Pages 622.e1-622.e16

  Jicha, Gregory A ^a,b   Abner, Erin L ^a,b   Schmitt, Frederick A ^a,b   Kryscio, Richard J ^a,b   Riley, Kathryn P ^a,b   Cooper, Gregory E ^a,b   Stiles, Nancy ^a,b   Mendiondo, Marta S ^a,b   Smith, Charles D ^a,b   Van Eldik, Linda J ^a,b   Nelson, Peter T ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Biomarkers; CSF; MRI; Neuropathology; Nondemented; Normal; Preclinical

Indexed keywords

AMYLOID;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; CEREBROVASCULAR DISEASE; COGNITION; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED STUDY; FEMALE; HIPPOCAMPAL SCLEROSIS; HISTOPATHOLOGY; HUMAN; MALE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PRIORITY JOURNAL;

EID: 84862907684     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.02.018     Document Type: Article

References (114)

1. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol. Aging 1997, 18(4 Suppl):S1-S2. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.
2. Aarsland D., Kurz M., Beyer M., Bronnick K., Piepenstock Nore S., Ballard C. Early discriminatory diagnosis of dementia with Lewy bodies. The emerging role of CSF and imaging biomarkers. Dement. Geriatr. Cogn. Disord 2008, 25:195-205.
3. Albert M.S., Moss M.B., Tanzi R., Jones K. Preclinical prediction of AD using neuropsychological tests. J. Int. Neuropsychol. Soc 2001, 7:631-639.
4. Preliminary Recommendations by Preclinical Alzheimer's Disease Workgroup Alzheimer's Association. http://www.alz.org/research/diagnostic_criteria/.
5. Arriagada P.V., Growdon J.H., Hedley-Whyte E.T., Hyman B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992, 42:631-639.
6. Arriagada P.V., Marzloff K., Hyman B.T. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 1992, 42:1681-1688.
7. Attems J., Jellinger K.A. Hippocampal sclerosis in Alzheimer disease and other dementias. Neurology 2006, 66:775.
8. Barker W.W., Luis C.A., Kashuba A., Luis M., Harwood D.G., Loewenstein D., Waters C., Jimison P., Shepherd E., Sevush S., Graff-Radford N., Newland D., Todd M., Miller B., Gold M., Heilman K., Doty L., Goodman I., Robinson B., Pearl G., Dickson D., Duara R. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis. Assoc. Disord 2002, 16:203-212.
9. Becker R.E., Greig N.H. Alzheimer's disease drug development in 2008 and beyond: problems and opportunities. Curr. Alzheimer Res 2008, 5:346-357.
10. Beckett L.A., Harvey D.J., Gamst A., Donohue M., Kornak J., Zhang H., Kuo J.H. The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. Alzheimers Dement 2010, 6:257-264. Alzheimer's Disease Neuroimaging Initiative.
11. Bennett D.A., Schneider J.A., Arvanitakis Z., Kelly J.F., Aggarwal N.T., Shah R.C., Wilson R.S. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006, 66:1837-1844.
12. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 2004, 1:213-225.
13. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259.
14. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259.
15. Braskie M.N., Klunder A.D., Hayashi K.M., Protas H., Kepe V., Miller K.J., Huang S.C., Barrio J.R., Ercoli L.M., Siddarth P., Satyamurthy N., Liu J., Toga A.W., Bookheimer S.Y., Small G.W., Thompson P.M. Plaque and tangle imaging and cognition in normal aging and Alzheimer's disease. Neurobiol. Aging 2010, 31:1669-1678.
16. Buerger K., Ewers M., Pirttila T., Zinkowski R., Alafuzoff I., Teipel S.J., DeBernardis J., Kerkman D., McCulloch C., Soininen H., Hampel H. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2006, 129:3035-3041.
17. Chertkow H., Black S. Imaging biomarkers and their role in dementia clinical trials. Can. J. Neurol. Sci 2007, 34(Suppl 1):S77-S83.
18. Chong M.S., Sahadevan S. Preclinical Alzheimer's disease: diagnosis and prediction of progression. Lancet Neurol 2005, 4:576-579.
19. Clark C.M., Xie S., Chittams J., Ewbank D., Peskind E., Galasko D., Morris J.C., McKeel D.W., Farlow M., Weitlauf S.L., Quinn J., Kaye J., Knopman D., Arai H., Doody R.S., DeCarli C., Leight S., Lee V.M., Trojanowski J.Q. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?. Arch. Neurol 2003, 60:1696-1702.
20. Crystal H., Dickson D., Fuld P., Masur D., Scott R., Mehler M., Masdeu J., Kawas C., Aronson M., Wolfson L. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 1988, 38:1682-1687.
21. Cummings J.L., Doody R., Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 2007, 69:1622-1634.
22. Davatzikos C., Bhatt P., Shaw L.M., Batmanghelich K.N., Trojanowski J.Q. Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification. Neurobiol. Aging 2010, 2010 Jun 29. 10.1016/j.neurobiolaging.2010.05.023.
23. Davis D.G., Schmitt F.A., Wekstein D.R., Markesbery W.R. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J. Neuropathol. Exp. Neurol 1999, 58:376-388.
24. de Leon M.J., Mosconi L., Blennow K., DeSanti S., Zinkowski R., Mehta P.D., Pratico D., Tsui W., Saint Louis L.A., Sobanska L., Brys M., Li Y., Rich K., Rinne J., Rusinek H. Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann. N.Y. Acad. Sci 2007, 1097:114-145.
25. Dickson D.W., Davies P., Bevona C., Van Hoeven K.H., Factor S.M., Grober E., Aronson M.K., Crystal H.A. Hippocampal sclerosis: a common pathological feature of dementia in very old (> or = 80 years of age) humans. Acta Neuropathol 1994, 88:212-221.
26. Dolan D., Troncoso J., Resnick S.M., Crain B.J., Zonderman A.B., O'Brien R.J. Age, Alzheimer's disease and dementia in the Baltimore Longitudinal Study of Ageing. Brain 2010, 133:2225-2231.
27. Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P.J., Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007, 6:734-746.
28. Engelborghs S., Sleegers K., Cras P., Brouwers N., Serneels S., De Leenheir E., Martin J.J., Vanmechelen E., Van Broeckhoven C., De Deyn P.P. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease. Brain 2007, 130:2320-2326.
29. Fagan A.M., Roe C.M., Xiong C., Mintun M.A., Morris J.C., Holtzman D.M. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol 2007, 64:343-349.
30. Gearing M., Mirra S.S., Hedreen J.C., Sumi S.M., Hansen L.A., Heyman A. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer's disease. Neurology 1995, 45:461-466.
31. Giannakopoulos P., Herrmann F.R., Bussière T., Bouras C., Kövari E., Perl D.P., Morrison J.H., Gold G., Hof P.R. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 2003, 60:1495-1500.
32. Gómez-Tortosa E., Gonzalo I., Fanjul S., Sainz M.J., Cantarero S., Cemillán C., Yébenes J.G., del Ser T. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. Arch. Neurol 2003, 60:1218-1222.
33. Guillozet A.L., Weintraub S., Mash D.C., Mesulam M.M. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch. Neurol 2003, 60:729-736.
34. Hachinski V., Iadecola C., Petersen R.C., Breteler M.M., Nyenhuis D.L., Black S.E., Powers W.J., DeCarli C., Merino J.G., Kalaria R.N., Vinters H.V., Holtzman D.M., Rosenberg G.A., Wallin A., Dichgans M., Marler J.R., Leblanc G.G. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 2006, 37:2220-2221.
35. Haense C., Herholz K., Jagust W.J., Heiss W.D. Performance of FDG PET for detection of Alzheimer's disease in two independent multicentre samples (NEST-DD and ADNI). Dement. Geriatr. Cogn. Disord 2009, 28:259-266.
36. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
37. Haroutunian V., Perl D.P., Purohit D.P., Marin D., Khan K., Lantz M., Davis K.L., Mohs R.C. Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch. Neurol 1998, 55:1185-1191.
38. Haroutunian V., Purohit D.P., Perl D.P., Marin D., Khan K., Lantz M., Davis K.L., Mohs R.C. Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. Arch. Neurol 1999, 56:713-718.
39. Hua X., Leow A.D., Parikshak N., Lee S., Chiang M.C., Toga A.W., Jack C.R., Weiner M.W., Thompson P.M. Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects. Neuroimage 2008, 43:458-469. Alzheimer's Disease Neuroimaging Initiative.
40. Hulette C.M., Welsh-Bohmer K.A., Murray M.G., Saunders A.M., Mash D.C., McIntyre L.M. Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J. Neuropathol. Exp. Neurol 1998, 57:1168-1174.
41. Jack C.R., Bernstein M.A., Borowski B.J., Gunter J.L., Fox N.C., Thompson P.M., Schuff N., Krueger G., Killiany R.J., Decarli C.S., Dale A.M., Carmichael O.W., Tosun D., Weiner M.W. Update on the magnetic resonance imaging core of the Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement 2010, 6:212-220.
42. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010, 9:119-128.
43. Jack C.R., Lowe V.J., Weigand S.D., Wiste H.J., Senjem M.L., Knopman D.S., Shiung M.M., Gunter J.L., Boeve B.F., Kemp B.J., Weiner M., Petersen R.C. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009, 132:1355-1365.
44. Jagust W.J., Bandy D., Chen K., Foster N.L., Landau S.M., Mathis C.A., Price J.C., Reiman E.M., Skovronsky D., Koeppe R.A. The Alzheimer'S Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement 2010, 6:221-229. Alzheimer's Disease Neuroimaging Initiative.
45. Jellinger K.A. Clinicopathological analysis of dementia disorders in the elderly--an update. J. Alzheimers Dis 2006, 9(3 Suppl):61-70.
46. Jellinger K.A., Attems J. Neurofibrillary tangle-predominant dementia: comparison with classical Alzheimer disease. Acta Neuropathol 2007, 113:107-117.
47. Jellinger K.A., Attems J. Neuropathological evaluation of mixed dementia. J. Neurol. Sci 2007, 257:80-87.
48. Jellinger K.A., Attems J. Prevalence of dementia disorders in the oldest-old: an autopsy study. Acta Neuropathol 2010, 119:421-433.
49. Jicha G.A., Parisi J.E., Dickson D.W., Cha R.H., Johnson K.A., Smith G.E., Boeve B.F., Petersen R.C., Knopman D.S. Age and apoE associations with complex pathologic features in Alzheimer's disease. J. Neurol. Sci 2008, 273:34-39.
50. Jicha G.A., Parisi J.E., Dickson D.W., Johnson K., Cha R., Ivnik R.J., Tangalos E.G., Boeve B.F., Knopman D.S., Braak H., Petersen R.C. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch. Neurol 2006, 63:674-681.
51. Jicha G.A., Schmitt F.A., Abner E., Nelson P.T., Cooper G.E., Smith C.D., Markesbery W.R. Prodromal clinical manifestations of neuropathologically confirmed Lewy body disease. Neurobiol. Aging 2010, 31:1805-1813.
52. Jobst K.A., Barnetson L.P., Shepstone B.J. Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and APO E4 medial temporal lobe dementias. The Oxford Project to Investigate Memory and Aging. Int. Psychogeriatr 1997, 9(Suppl 1):191-222. discussion 47-52.
53. Johnson K.A., Jones K., Holman B.L., Becker J.A., Spiers P.A., Satlin A., Albert M.S. Preclinical prediction of Alzheimer's disease using SPECT. Neurology 1998, 50:1563-1571.
54. Kalaria R.N., Maestre G.E., Arizaga R., Friedland R.P., Galasko D., Hall K., Luchsinger J.A., Ogunniyi A., Perry E.K., Potocnik F., Prince M., Stewart R., Wimo A., Zhang Z.X., Antuono P. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol 2008, 7:812-826.
55. Kapaki E., Paraskevas G.P., Zalonis I., Zournas C. CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population. Eur. J. Neurol 2003, 10:119-128.
56. Katzman R., Terry R., DeTeresa R., Brown T., Davies P., Fuld P., Renbing X., Peck A. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann. Neurol 1988, 23:138-144.
57. Khachaturian Z.S. Diagnosis of Alzheimer's disease. Arch. Neurol 1985, 42:1097-1105.
58. Knopman D.S., Parisi J.E., Salviati A., Floriach-Robert M., Boeve B.F., Ivnik R.J., Smith G.E., Dickson D.W., Johnson K.A., Petersen L.E., McDonald W.C., Braak H., Petersen R.C. Neuropathology of cognitively normal elderly. J. Neuropathol. Exp. Neurol 2003, 62:1087-1095.
59. LeVine H. Multiple ligand binding sites on A beta(1-40) fibrils. Amyloid 2005, 12:5-14.
60. Li Y., Rinne J.O., Mosconi L., Pirraglia E., Rusinek H., Desanti S., Kemppainen N., Nagren K., Kim B.C., Tsui W., de Leon M.J. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:2169-2181.
61. Lockhart A., Lamb J.R., Osredkar T., Sue L.I., Joyce J.N., Ye L., Libri V., Leppert D., Beach T.G. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain 2007, 130:2607-2615.
62. Markesbery W.R., Jicha G.A., Liu H., Schmitt F.A. Lewy body pathology in normal elderly subjects. J. Neuropathol. Exp. Neurol 2009, 68:816-822.
63. Markesbery W.R., Schmitt F.A., Kryscio R.J., Davis D.G., Smith C.D., Wekstein D.R. Neuropathologic substrate of mild cognitive impairment. Arch. Neurol 2006, 63:38-46.
64. McKeith I.G. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J. Alzheimers Dis 2006, 9(3 suppl):417-423.
65. McKeith I.G., Ince P., Jaros E.B., Fairbairn A., Ballard C., Grace J., Morris C.M., Perry R.H. What are the relations between Lewy body disease and AD?. J. Neural Transm. Suppl 1998, 54:107-116.
66. Mintun M.A., Larossa G.N., Sheline Y.I., Dence C.S., Lee S.Y., Mach R.H., Klunk W.E., Mathis C.A., DeKosky S.T., Morris J.C. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006, 67:446-452.
67. Misra C., Fan Y., Davatzikos C. Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: results from ADNI. Neuroimage 2009, 44:1415-1422.
68. Molano J., Boeve B., Ferman T., Smith G., Parisi J., Dickson D., Knopman D., Graff-Radford N., Geda Y., Lucas J., Kantarci K., Shiung M., Jack C., Silber M., Pankratz V.S., Petersen R. Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study. Brain 2010, 133:540-556.
69. Mollenhauer B., Bibl M., Trenkwalder C., Stiens G., Cepek L., Steinacker P., Ciesielczyk B., Neubert K., Wiltfang J., Kretzschmar H.A., Poser S., Otto M. Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease. J. Neural Transm 2005, 112:933-948.
70. Mollenhauer B., Cepek L., Bibl M., Wiltfang J., Schulz-Schaeffer W.J., Ciesielczyk B., Neumann M., Steinacker P., Kretzschmar H.A., Poser S., Trenkwalder C., Otto M. Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement. Geriatr. Cogn. Disord 2005, 19:164-170.
71. Mormino E.C., Kluth J.T., Madison C.M., Rabinovici G.D., Baker S.L., Miller B.L., Koeppe R.A., Mathis C.A., Weiner M.W., Jagust W.J. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009, 132:1310-1323.
72. Morris J.C., Price A.L. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J. Mol. Neurosci 2001, 17:101-118.
73. Morris J.C., Roe C.M., Grant E.A., Head D., Storandt M., Goate A.M., Fagan A.M., Holtzman D.M., Mintun M.A. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch. Neurol 2009, 66:1469-1475.
74. Morris J.C., Weintraub S., Chui H.C., Cummings J., Decarli C., Ferris S., Foster N.L., Galasko D., Graff-Radford N., Peskind E.R., Beekly D., Ramos E.M., Kukull W.A. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis. Assoc. Disord 2006, 20:210-216.
75. Nelson P.T., Abner E.L., Schmitt F.A., Kryscio R.J., Jicha G.A., Santacruz K., Smith C.D., Patel E., Markesbery W.R. Brains with medial temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are a diagnostic dilemma but may have pathogenetic aspects distinct from Alzheimer disease. J. Neuropathol. Exp. Neurol 2009, 68:774-784.
76. Nelson P.T., Abner E.L., Schmitt F.A., Kryscio R.J., Jicha G.A., Smith C.D., Davis D.G., Poduska J.W., Patel E., Mendiondo M.S., Markesbery W.R. Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathol 2010, 20:66-79.
77. Nelson P.T., Braak H., Markesbery W.R. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J. Neuropathol. Exp. Neurol 2009, 68:1-14.
78. Nelson P.T., Jicha G.A., Schmitt F.A., Liu H., Davis D.G., Mendiondo M.S., Abner E.L., Markesbery W.R. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity. J. Neuropathol. Exp. Neurol 2007, 66:1136-1146.
79. Nelson P.T., Kukull W.A., Frosch M.P. Thinking outside the box: Alzheimer-type neuropathology that does not map directly onto current consensus recommendations. J. Neuropathol. Exp. Neurol 2010, 69:449-454.
80. Nelson P.T., Schmitt F.A., Lin Y., Abner E.L., Jicha G.A., Patel E., Thomason P.C., Neltner J.H., Smith C.D., Santacruz K.S., Sonnen J.A., Poon L.W., Gearing M., Green R.C., Woodard J.L., Van Eldik L.J., Kryscio R.J. Hippocampal sclerosis in advanced age: clinical and pathological features in 106 cases. Brain 2011, in press, In press. 10.1093/brain/awr053.
81. Peskind E.R., Li G., Shofer J., Quinn J.F., Kaye J.A., Clark C.M., Farlow M.R., DeCarli C., Raskind M.A., Schellenberg G.D., Lee V.M., Galasko D.R. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch. Neurol 2006, 63:936-939.
82. Petersen R.C., Doody R., Kurz A., Mohs R.C., Morris J.C., Rabins P.V., Ritchie K., Rossor M., Thal L., Winblad B. Current concepts in mild cognitive impairment. Arch. Neurol 2001, 58:1985-1992.
83. Petersen R.C., Negash S. Mild cognitive impairment: an overview. CNS Spectr 2008, 13:45-53.
84. Pike K.E., Savage G., Villemagne V.L., Ng S., Moss S.A., Maruff P., Mathis C.A., Klunk W.E., Masters C.L., Rowe C.C. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007, 130:2837-2844.
85. Potkin S.G., Guffanti G., Lakatos A., Turner J.A., Kruggel F., Fallon J.H., Saykin A.J., Orro A., Lupoli S., Salvi E., Weiner M., Macciardi F. Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease. PLoS One 2009, 4:e6501.
86. Price J.L., McKeel D.W., Buckles V.D., Roe C.M., Xiong C., Grundman M., Hansen L.A., Petersen R.C., Parisi J.E., Dickson D.W., Smith C.D., Davis D.G., Schmitt F.A., Markesbery W.R., Kaye J., Kurlan R., Hulette C., Kurland B.F., Higdon R., Kukull W., Morris J.C. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol. Aging 2009, 30:1026-1036.
87. Prins N.D., van Dijk E.J., den Heijer T., Vermeer S.E., Koudstaal P.J., Oudkerk M., Hofman A., Breteler M.M. Cerebral white matter lesions and the risk of dementia. Arch. Neurol 2004, 61:1531-1534.
88. Risacher S.L., Saykin A.J., West J.D., Shen L., Firpi H.A., McDonald B.C. Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr. Alzheimer Res 2009, 6:347-361.
89. Risacher S.L., Shen L., West J.D., Kim S., McDonald B.C., Beckett L.A., Harvey D.J., Jack C.R., Weiner M.W., Saykin A.J. Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort. Neurobiol. Aging 2010, 31:1401-1418.
90. Rowe C.C., Ng S., Ackermann U., Gong S.J., Pike K., Savage G., Cowie T.F., Dickinson K.L., Maruff P., Darby D., Smith C., Woodward M., Merory J., Tochon-Danguy H., O'Keefe G., Klunk W.E., Mathis C.A., Price J.C., Masters C.L., Villemagne V.L. Imaging beta-amyloid burden in aging and dementia. Neurology 2007, 68:1718-1725.
91. Sabbagh M.N. Drug development for Alzheimer's disease: where are we now and where are we headed?. Am. J. Geriatr. Pharmacother 2009, 7:167-185.
92. Schmitt F.A., Davis D.G., Wekstein D.R., Smith C.D., Ashford J.W., Markesbery W.R. "Preclinical" AD revisited: neuropathology of cognitively normal older adults. Neurology 2000, 55:370-376.
93. Schmitt F.A., Wetherby M.M., Wekstein D.R., Dearth C.M., Markesbery W.R. Brain donation in normal aging: procedures, motivations, and donor characteristics from the Biologically Resilient Adults in Neurological Studies (BRAiNS) Project. Gerontologist 2001, 41:716-722.
94. Schneider J.A., Aggarwal N.T., Barnes L., Boyle P., Bennett D.A. The neuropathology of older persons with and without dementia from community versus clinic cohorts. J. Alzheimers Dis 2009, 18:691-701.
95. Schneider J.A., Arvanitakis Z., Leurgans S.E., Bennett D.A. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann. Neurol 2009, 66:200-208.
96. Smith C.D., Chebrolu H., Wekstein D.R., Schmitt F.A., Jicha G.A., Cooper G., Markesbery W.R. Brain structural alterations before mild cognitive impairment. Neurology 2007, 68:1268-1273.
97. Stomrud E., Hansson O., Blennow K., Minthon L., Londos E. Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement. Geriatr. Cogn. Disord 2007, 24:118-124.
98. Stomrud E., Hansson O., Minthon L., Blennow K., Rosen I., Londos E. Slowing of EEG correlates with CSF biomarkers and reduced cognitive speed in elderly with normal cognition over 4 years. Neurobiol. Aging 2010, 31:215-223.
99. Thal D.R., Del Tredici K., Braak H. Neurodegeneration in normal brain aging and disease. Sci. Aging Knowl. Environ 2004, 23:pe26.
100. Thompson P.W., Ye L., Morgenstern J.L., Sue L., Beach T.G., Judd D.J., Shipley N.J., Libri V., Lockhart A. Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies. J. Neurochem 2009, 109:623-630.
101. Tierney M.C., Szalai J.P., Snow W.G., Fisher R.H., Nores A., Nadon G., Dunn E., St George-Hyslop P.H. Prediction of probable Alzheimer's disease in memory-impaired patients: A prospective longitudinal study. Neurology 1996, 46:661-665.
102. Tierney M.C., Yao C., Kiss A., McDowell I. Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years. Neurology 2005, 64:1853-1859.
103. Tomlinson B.E., Blessed G., Roth M. Observations on the brains of non-demented old people. J. Neurol. Sci 1968, 7:331-356.
104. Troncoso J.C., Martin L.J., Dal Forno G., Kawas C.H. Neuropathology in controls and demented subjects from the Baltimore Longitudinal Study of Aging. Neurobiol. Aging 1996, 17:365-371.
105. Vanderstichele H., De Vreese K., Blennow K., Andreasen N., Sindic C., Ivanoiu A., Hampel H., Bürger K., Parnetti L., Lanari A., Padovani A., DiLuca M., Bläser M., Olsson A.O., Pottel H., Hulstaert F., Vanmechelen E. Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin. Chem. Lab. Med 2006, 44:1472-1480.
106. Walhovd K.B., Fjell A.M., Brewer J., McEvoy L.K., Fennema-Notestine C., Hagler D.J., Jennings R.G., Karow D., Dale A.M. Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR Am. J. Neuroradiol 2010, 31:347-354.
107. Watson G.S., Cholerton B.A., Reger M.A., Baker L.D., Plymate S.R., Asthana S., Fishel M.A., Kulstad J.J., Green P.S., Cook D.G., Kahn S.E., Keeling M.L., Craft S. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry 2005, 13:950-958.
108. Weiner M.W., Aisen P.S., Jack C.R., Jagust W.J., Trojanowski J.Q., Shaw L., Saykin A.J., Morris J.C., Cairns N., Beckett L.A., Toga A., Green R., Walter S., Soares H., Snyder P., Siemers E., Potter W., Cole P.E., Schmidt M. The Alzheimer's Disease Neuroimaging Initiative: progress report and future plans. Alzheimers Dement 2010, 6:202-211.e7. Alzheimer's Disease Neuroimaging Initiative.
109. Weintraub S., Salmon D., Mercaldo N., Ferris S., Graff-Radford N.R., Chui H., Cummings J., DeCarli C., Foster N.L., Galasko D., Peskind E., Dietrich W., Beekly D.L., Kukull W.A., Morris J.C. The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis. Assoc. Disord 2009, 23:91-101.
110. Whitwell J.L., Josephs K.A., Murray M.E., Kantarci K., Przybelski S.A., Weigand S.D., Vemuri P., Senjem M.L., Parisi J.E., Knopman D.S., Boeve B.F., Petersen R.C., Dickson D.W., Jack C.R. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 2008, 71:743-749.
111. Winblad B., Palmer K., Kivipelto M., Jelic V., Fratiglioni L., Wahlund L.O., Nordberg A., Bäckman L., Albert M., Almkvist O., Arai H., Basun H., Blennow K., de Leon M., DeCarli C., Erkinjuntti T., Giacobini E., Graff C., Hardy J., Jack C., Jorm A., Ritchie K., van Duijn C., Visser P., Petersen R.C. Mild cognitive impairment--beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J. Intern. Med 2004, 256:240-246.
112. Yoshita M., Fletcher E., Harvey D., Ortega M., Martinez O., Mungas D.M., Reed B.R., DeCarli C.S. Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD. Neurology 2006, 67:2192-2198.
113. Zaccai J., Ince P., Brayne C. Population-based neuropathological studies of dementia: Design, methods and areas of investigation--a systematic review. BMC Neurol 2006, 6:2.
114. Zekry D., Hauw J.J., Gold G. Mixed dementia: epidemiology, diagnosis, and treatment. J. Am. Geriatr. Soc 2002, 50:1431-1438.